Scientific Publications - SinoMab BioScience Limited

2024 Jun

Lam LH, Li W, Wu WC, Chow KC, Au WYD, Xu G, Wang G, Qian X, Ng KM, Nawabjan SA, Gandhi Sethuraman MI, Choi WY, Chow BKC, Leung SO, Hui CW.

SM17, a New IL-17RB-targeting Antibody, Ameliorates Disease Progression in a Mouse Model of Atopic Dermatitis.

Allergy 2024. 79:1625-1628.

https://pubmed.ncbi.nlm.nih.gov/38590291/

2023 Dec

Wu WC, Shiu C, Tong TK, Leung SO, Hui CW.

Suppression of NK Cell Activation by JAK3 Inhibition: Implication in the Treatment of Autoimmune Diseases.

J Immunol Res 2023. 2023:8924603.

https://pubmed.ncbi.nlm.nih.gov/38106519/

2023 Oct

Zhu L, Shi R, Zhao T, Ye Y, Tang J, Hu Y, Peng P, Wang D, Chong C, Xu G, Leung SO, Yuan W.

A Randomized, Controlled Single, and Multiple Ascending Dose Trial of the Safety, Pharmacokinetics and Pharmacodynamics of SN1011 in Healthy Subjects.

Clin Transl Sci 2023. 16:1982-1996.

https://pubmed.ncbi.nlm.nih.gov/37551782/

2022 Jul

Hui CW, Wu WC, Leung SO.

Interleukins 4 and 21 Protect Anti-IgM Induced Cell Death in Ramos B Cells: Implication for Autoimmune Diseases.

Front Immunol 2022. 13:919854.

https://pubmed.ncbi.nlm.nih.gov/35911775/

2022 Jun

Wong KL, Li Z, Ma F, Wang D, Song N, Chong CH, Luk KK, Leung SO.

SM03, an Anti-CD22 Antibody, Converts Cis-to-Trans Ligand Binding of CD22 against α2,6-Linked Sialic Acid Glycans and Immunomodulates Systemic Autoimmune Diseases.

J Immunol 2022. 208:2726-2737.

https://pubmed.ncbi.nlm.nih.gov/35688465/

2022 May

Wong KL, LLi J, Li M, Wu D, Zhou J, Leung SO, Zhang F.

SM03, an Anti-human CD22 Monoclonal Antibody, for Active Rheumatoid Arthritis: a Phase II, Randomized, Double-blind, Placebo-controlled Study.

Rheumatology (Oxford) 2022. 61:1841-1848.

https://pubmed.ncbi.nlm.nih.gov/34508557/

2021 Nov

Zhao Q, Chen X, Jiang J, Li J, Zhong W, Han H, Li Z, Leung SO, Zhang F, Hu P.

An Open-label, Multiple-dose Study to Assess the Preliminary Pharmacokinetics, Pharmacodynamics, Clinical Activity, and Safety of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Patients with Rheumatoid Arthritis.

Int J Clin Pharmacol Ther 2021. 59:691-704.

https://pubmed.ncbi.nlm.nih.gov/34423769/

2016 Nov

Zhao Q, Chen X, Li J, Jiang J, Li M, Zhong W, Li Z, Leung SO, Zhang F, Hu P.

Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus.

Clin Drug Investig 2016. 36:889-902

https://pubmed.ncbi.nlm.nih.gov/27424629/

2015 Jan-Feb

Leung SO, Gao K, Wang GY, Cheung BK, Lee KY, Zhao Q, Cheung WT, Wang JZ.

Surrogate Target Cells Expressing Surface Anti-idiotype Antibody for the Clinical Evaluation of an Internalizing CD22-specific Antibody.

MAbs 2015. 7:66-76.

https://pubmed.ncbi.nlm.nih.gov/25427174/

2014 May

Zhao Q, Wong PF, Lee SS, Leung SO, Cheung WT, Wang JZ.

Generation of Anti-idiotype scFv for Pharmacokinetic Measurement in Lymphoma Patients Treated with Chimera Anti-CD22 Antibody SM03.

PLoS One 2014. 9:e96697.

https://pubmed.ncbi.nlm.nih.gov/24816427/